Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
Phase 2
Recruiting
- Conditions
- Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaAcute Myeloid Leukemia
- Interventions
- Drug: BusulfanDrug: CladribineDrug: Fludarabine PhosphateProcedure: Hematopoietic Cell TransplantationDrug: ThiotepaDrug: Venetoclax
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 324
- Registration Number
- NCT04708054
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
Phase 2
Active, not recruiting
- Conditions
- Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Neuroendocrine CarcinomaLung Small Cell Carcinoma
- Interventions
- First Posted Date
- 2021-01-08
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT04701307
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
Not Applicable
Recruiting
- Conditions
- Castration-Resistant Prostate CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Colorectal CarcinomaStage IVA Prostate Cancer AJCC v8Metastatic Thyroid Gland CarcinomaMetastatic Urothelial CarcinomaStage IV Colorectal Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Metastatic Malignant Solid Neoplasm
- Interventions
- Procedure: CryosurgeryOther: Quality-of-Life AssessmentRadiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04693377
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
Phase 1
Recruiting
- Conditions
- Metastatic Malignant Solid NeoplasmAdvanced Malignant Solid NeoplasmRecurrent Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 111
- Registration Number
- NCT04693468
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Acceptability of 3D Printed Breast Models as Surgical Decision Aids for Breast Cancer Treatment
Completed
- Conditions
- Breast Carcinoma
- Interventions
- Other: Decision AidProcedure: DiscussionOther: Questionnaire Administration
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT04693364
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer
Recruiting
- Conditions
- Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Endometrial CarcinomaPrognostic Stage IIIA Breast Cancer AJCC v8Female Reproductive System DisorderPrognostic Stage I Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8
- Interventions
- Behavioral: Healthcare ActivityOther: Survey Administration
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1410
- Registration Number
- NCT04678414
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
Not Applicable
Recruiting
- Conditions
- Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm
- Interventions
- Other: 6 Minute Walk Functional TestBehavioral: Behavioral InterventionOther: Survey AdministrationBehavioral: Timed Get Up and Go Test
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04678427
- Locations
- 🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
Phase 2
Recruiting
- Conditions
- Thyroid Gland Anaplastic CarcinomaThyroid Gland Squamous Cell Carcinoma
- Interventions
- Procedure: Conventional SurgeryDrug: DabrafenibRadiation: Intensity-Modulated Radiation TherapyBiological: PembrolizumabOther: Quality-of-Life AssessmentDrug: Trametinib
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT04675710
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Stanford School of Medicine, Stanford, California, United States
ALI Post Radiation Therapy in Patients With Lung and Esophageal Canter
Phase 2
Active, not recruiting
- Conditions
- Solid Tumor Malignancies
- Interventions
- Procedure: Autologous lymphocyte infusion (ALI)
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT04668833
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
Phase 2
Recruiting
- Conditions
- Metastatic AngiosarcomaRefractory Dedifferentiated LiposarcomaMetastatic Dedifferentiated LiposarcomaRefractory OsteosarcomaRecurrent OsteosarcomaMetastatic OsteosarcomaRecurrent AngiosarcomaRecurrent Dedifferentiated Liposarcoma
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT04668300
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath